https://prabadinews.com/
  • October 8, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

EHA 2025: BMS-986458 Shows Clinical Promise in FL and DLBCL

EHA 2025: BMS-986458 Shows Clinical Promise in FL and DLBCL

Franck Morschhauser, MD, PhD, discusses the novel cereblon-dependent bifunctional degrader BMS-986458, highlighting its selective targeting of BCL6, promising early efficacy in relapsed/refractory lymphoma, favorable safety profile, and future potential in combination regimens and earlier treatment lines.

administrator

Related Articles